← back to search

R. Kiplin Guy

University of Kentucky · US
Area of research
Public Health, Environmental and Occupational Health · Genetics
Research interest
Research interests include Malaria Research and Control, Estrogen and related hormone effects, Cancer Treatment and Pharmacology, and Computational Drug Discovery Methods.
h-index
61
citations
14,954
works
303
NIH funding
primary concept
Chemistry
email

Recent publications

Antitrypanosomal Chloronitrobenzamides
Journal of Medicinal Chemistry 2024cited by 7position: contributordoi
Optimization of diastereomeric dihydropyridines as antimalarials
European Journal of Medicinal Chemistry 2024cited by 1position: middledoi
Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia
Nature Communications 2023cited by 20position: middledoi
Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia.
2023cited by 16position: contributordoi
Optimization of Orally Bioavailable Antileishmanial 2,4,5-Trisubstituted Benzamides
Journal of Medicinal Chemistry 2023cited by 11position: contributordoi
Author Correction: Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia.
2023cited by 0position: contributordoi
Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M.
2021cited by 13position: contributordoi
Amino-Substituted 3-Aryl- and 3-Heteroarylquinolines as Potential Antileishmanial Agents
Journal of Medicinal Chemistry 2021cited by 11position: contributordoi
Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones
2021cited by 0position: contributordoi
Synthesis and Structure-Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4-<i>b</i>]pyridines.
2020cited by 12position: contributordoi
Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones
2020cited by 0position: contributordoi
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.
2019cited by 31position: contributordoi
Discovery of Novel Pyrazolo-pyridone DCN1 Inhibitors Controlling Cullin Neddylation.
2019cited by 27position: contributordoi
Ventromorphins: A New Class of Small Molecule Activators of the Canonical BMP Signaling Pathway.
2019cited by 6position: contributordoi
Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation
Journal of Medicinal Chemistry 2018cited by 61position: lastdoi
Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation
Journal of Medicinal Chemistry 2018cited by 42position: lastdoi
Oxazole and Thiazole Analogs of Sulindac for Cancer Prevention
Future Medicinal Chemistry 2018cited by 15position: middledoi
A small diversity library of α-methyl amide analogs of sulindac for probing anticancer structure-activity relationships
Bioorganic & Medicinal Chemistry Letters 2018cited by 10position: middledoi
Blocking an N-terminal acetylation–dependent protein interaction inhibits an E3 ligase
Nature Chemical Biology 2017cited by 110position: lastdoi
Diverse amide analogs of sulindac for cancer treatment and prevention
Bioorganic & Medicinal Chemistry Letters 2017cited by 24position: middledoi
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond
PLoS Pathogens 2016cited by 446position: middledoi
Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles
ACS Central Science 2016cited by 105position: middledoi
Monitoring Ligand-Induced Protein Ordering in Drug Discovery
Journal of Molecular Biology 2016cited by 33position: middledoi
Screening and Development of New Inhibitors of FtsZ from M. Tuberculosis
PLoS ONE 2016cited by 25position: middledoi
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of <i>Plasmodium</i>
Proceedings of the National Academy of Sciences 2014cited by 247position: lastdoi
Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma
Cancer Cell 2014cited by 146position: middledoi
Pharmacokinetics and Efficacy of the Spleen Tyrosine Kinase Inhibitor R406 after Ocular Delivery for Retinoblastoma
Pharmaceutical Research 2014cited by 26position: middledoi
Treatment of Murine Cerebral Malaria by Artemisone in Combination with Conventional Antimalarial Drugs: Antiplasmodial Effects and Immune Responses
Antimicrobial Agents and Chemotherapy 2014cited by 18position: middledoi
On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53
PLoS ONE 2012cited by 57position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

· 12 papers (2019–2024) · 6 papers (2016–2018)Robert C. Reynolds · University of Alabama at Birmingham4 papers (2016–2018) · 4 papers (2016–2018)Jaeki Min · Amgen (United States)4 papers (2012–2018)AA Shelat · Novartis Institutes for BioMedical Research4 papers (2019–2023)Judith V. Hobrath · University of Alabama at Birmingham3 papers (2016–2018)Hiroto Inaba · Mercy Children's Hospital3 papers (2019–2023)Michael A. Dyer · Phoenix Contact (United States)3 papers (2012–2016)Lei Yang · Nanjing University of Chinese Medicine3 papers (2014–2018) · 2 papers (2014–2016)Jeffrey E. Rubnitz · Children's Hospital2 papers (2023–2023)Bhuvanesh Singh · Northwestern University2 papers (2018–2018)Taosheng Chen · Guangdong University of Technology2 papers (2023–2023)Mark E. Hatley · St. Jude Children's Research Hospital2 papers (2023–2023) · 2 papers (2023–2023)Jaeki Min · Sungkyunkwan University2 papers (2019–2019)Duane Currier · United States Army Medical Research Institute of Infectious Diseases2 papers (2023–2023)John K. Choi · Korea Advanced Institute of Science and Technology2 papers (2023–2023)Brenda A. Schulman · Max Planck Institute of Biophysics2 papers (2019–2021)